本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Viking Therapeutics, Inc.

40.76
+0.15500.38%
成交量:388.46萬
成交額:1.61億
市值:46.07億
市盈率:-19.23
高:43.15
開:42.09
低:40.01
收:40.60
52周最高:62.50
52周最低:18.92
股本:1.13億
流通股本:1.10億
量比:1.67
換手率:3.53%
股息:- -
股息率:- -
每股收益(TTM):-2.1195
每股收益(LYR):-1.0085
淨資產收益率:-29.23%
總資產收益率:-20.48%
市淨率:6.46
市盈率(LYR):-40.41

資料載入中...

2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/15

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/08

關聯方擬減持公告

Form 144 | VIKING THERAPEUTICS, INC. 董事 Lawson Macartney 擬減持2000股,總價約13.73萬美元
2024/11/04

重要事件披露

Form 8-K - Current report
2024/10/28

關聯方擬減持公告

Form 144 | Viking Therapeutics高管Greg Zante擬減持131687股,總價約1028萬美元
2024/10/25

關聯方擬減持公告

Form 144 | Viking Therapeutics董事 Rouan Sarah Kathryn 擬減持11000股,總價約88.94萬美元
2024/10/25

關聯方擬減持公告

Form 144 | Viking Therapeutics董事 Singleton擬減持16000股,總價約127萬美元
2024/10/23

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/23

重要事件披露

Form 8-K - Current report
2024/10/18

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/09/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/21

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/21

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/14

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/07/30

關聯方擬減持公告

Form144 | Viking Therapeutics高管Greg Zante擬減持16136股,總價約92.2萬美元